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ABSTRACT
Objective The objective of this study was to evaluate
peer support and reminiscence therapy, separately and
together, in comparison with usual care for people with
dementia and their family carers.
Design Factorial pragmatic randomised trial, analysed
by treatment allocated, was used for this study.
Setting The trial ran in Community settings in England.
Participants People with dementia and their family
carers were the participants.
Interventions Treatment as usual (TAU) plus one of
the following: one-to-one peer support to family carers
from experienced carers (Carer Supporter Programme;
CSP), group reminiscence therapy (Remembering
Yesterday, Caring Today; RYCT) for people with
dementia and carers, both or neither.
Main outcome measures Primary outcomes included
health-related quality of life (SF-12) for carers and
quality of life (QoL-AD) for people with dementia;
secondary outcomes included quality of relationship for
carers and people with dementia; both were collected by
blinded assessors at baseline, 5 and 12 months (primary
end point).
Results Of 291 pairs recruited, we randomised 145
(50%) to CSP (71% uptake) and 194 (67%) to RYCT
(61% uptake). CSP and RYCT, separately or together,
were not effective in improving primary outcomes or
most secondary outcomes. For CSP versus ‘no CSP’,
adjusted difference in means was 0.52 points on the SF-
12 (95% CI −1.28 to 2.32) and −0.08 points on the
QoL-AD (95% CI −1.70 to 1.56). For RYCT versus ‘no
RYCT’, the difference was 0.10 points on the SF-12
(95% CI −1.72 to 1.93) and 0.51 points on the QoL-
AD (95% CI −1.17 to 2.08). However, carers reported
better relationships with the people with dementia
(difference 1.11, 95% CI 0.00 to 2.21, p=0.05).
Comparison of combined intervention with TAU, and of
intervention received, suggested differential impacts for
carers and persons with dementia.
Conclusions There is no evidence from the trial that
either peer support or reminiscence is effective in
improving the quality of life.
Trial registration number ISRCTN37956201;
Results.
INTRODUCTION
The lack of progress in new drug treatments for
people with dementia has contrasted with recent
advances in psychological interventions. In the UK,
there have been large randomised controlled
trials of cognitive–behavioural therapy (CBT)1 and
befriending2 as interventions for carers, cognitive
stimulation therapy (CST)3 for people with demen-
tia and reminiscence therapy4 for carers and people
with dementia. The evaluations of CBT for carers
and CST for people with dementia have demon-
strated the effectiveness of these interventions in
reducing distress and maintaining cognition,
respectively. In contrast, there is no evidence that
befriending2 or joint reminiscence4 reduces distress,
even though they are recommended in clinical
guidelines5 and remain popular in practice. Peer
support may be more effective than befriending in
addressing carers’ needs and may also enhance
reminiscence therapy. Hence, this trial aimed to
evaluate two psychological interventions, namely
one-to-one peer support for carers (Carer
Supporter Programme; CSP) and group reminis-
cence therapy for people with dementia and their
carers (Remembering Yesterday Caring Today;
RYCT), together and separately.
METHODS
The trial protocol6 describes the research question,
sample size calculation, recruitment, consent,
randomisation, interventions, outcome measures,
ethical considerations and research governance.
Design
We used a multisite, 2×2 factorial, pragmatic ran-
domised trial. The factorial design in effect is ‘two
trials in one’, enabling us to evaluate both treat-
ments. We consented participating carers, collected
baseline data and randomised them individually
between CSP and treatment as usual (TAU), and
then randomised them between RYCT groups and
TAU. This created four arms—CSP, RYCT, CSP and
RYCT, and TAU alone. To yield enough participants
to run viable RYCT groups, randomisations
between TAU, CSP, RYCT and CSP–RYCT were in
the proportions of 1:2:1:2. At the first randomisa-
tion, we stratified by kinship (whether carers were
spouses or offspring) and centre. At the second ran-
domisation, we also stratified by the first allocation
to keep the four arms in balance. We collected
follow-up data 5 and 12 months (main end point)
after the first randomisation.
In accordance with MRC guidance on develop-
ing and evaluating complex interventions,7 we
piloted in two London boroughs before the full
trial: the first borough reviewed the
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appropriateness and acceptability of procedures, and the second
borough checked logistics and timing of the interventions. We
described the resulting decisions on pooling pilot and main trial
data elsewhere.8 As changes between pilot and full trial were
minimal, we carried pilot data forward to the full trial.
Ethics approval
The Outer North East London Research Ethics Committee gave
written ethics approval (09/H0701/54). We obtained Research
and Development approval from local trusts. All participants
gave written informed consent.
Setting
The trial ran in community settings in London, Berkshire,
Norfolk and Northamptonshire.
Eligibility criteria
Participants were adult (18 years and over) family carers and
their relative with dementia (as defined by DSM-IV criteria)
living at home in the community. We excluded carers if they or
their protégés had learning disability, non-progressive brain
injury or diagnosed terminal illness, or they were already taking
part in another psychosocial intervention study.
Sample size
We based sample size on the BECCA2 and REMCARE4 trials.
These predicted effect sizes, namely average effect per partici-
pant divided by population SD, of 0.42 for CSP and 0.35 for
RYCT. Hence, a completed sample of 240 pairs would yield
power of more than 90% to detect these effects using a signifi-
cance level of 5%. This would also yield power of more than
80% to detect interaction between CSP and RYCTequivalent to
an effect size of 0.4. Assuming 80% retention, we aimed to
recruit 300 pairs of carers and people with dementia.
Interventions
For CSP, volunteer carer supporters (CSs) were recruited locally
by CS Coordinators and attended a mandatory ‘Being a Carer
Supporter’ orientation and awareness course before being
matched with a family carer participant. The target ‘dose’ was
12 weekly meetings of 1 hour, followed by fortnightly meetings
for the next 5 months, 22 hours in total. Meetings took place in
the carer’s own home, or a public venue like a café, or over the
telephone, and could include or exclude the person with
dementia according to the preference of the family carer. We
asked CSs to listen, encourage and give moral support. Though
they could also signpost to resources and services, we instructed
them not to offer tangible support, respite or direct advice.
The RYCT intervention followed Schweitzer and Bruce’s9
programme. Twelve weekly sessions took place in community
venues, each lasting 2 hours, covered themes across the lifespan,
using multisensory triggers and activities, such as group discus-
sions, small group activity, handling objects, acting or improvisa-
tion, and singing. During four sessions, the family carers met
separately from the main group for ∼45 min with the aim of
developing listening and communication skills, and considering
how the activities and strategies in the sessions could continue
in the home. After the weekly sessions, monthly sessions contin-
ued for 7 months, giving a possible 19 sessions over 10 months.
To address the potential time burden of the combined interven-
tion, we invited CSs to meet their matched carers at the RYCT
sessions.
We had a planned protocol for assessing intervention delivery
and receipt.10 Delivery of CSP was monitored by local CS
Coordinators through monthly completion of checklists, and
RYCT adherence was recorded for each session by a participat-
ing research assistant. We ensured that all participants continued
to receive the TAU available in their area and gave them lists of
useful local resources.
Measures
We collected demographic information for carer and person
with dementia, including age, gender, education, kinship and
living circumstances. We characterised carers’ social networks
according to the Practitioner Assessment of Network Typology
(PANT).11 We measured the cognitive status of the person with
dementia by the mini-mental state examination (MMSE)12 and
the interviewer rated the clinical dementia rating (CDR).13
Primary outcomes
The primary outcome was family carers’ mental health-related
quality of life, measured by the mental component score of the
UK Short Form-12 Health Survey (UK SF-12).14 15 The SF-12
covers physical functioning, social functioning, role functioning
(physical and mental), vitality, bodily pain, mental health and
general health, and it generates mental and physical component
scores (MCS-12 and PCS-12, respectively).
The primary outcome for the person with dementia was
quality of life measured by the 13-item Quality of Life—
Alzheimer’s Disease Scale (QoL-AD).16 Responses for both ver-
sions—completed by self or proxy—range from poor (1),
through fair and good to excellent (4), yielding totals in the
range between 13 and 52.
Secondary outcomes for family carers
Health-related quality of life using the EQ-5D17 comprising five
items generating a single utility score and a visual analogue scale
(VAS) to rate one’s general health, Hospital Anxiety and
Depression Scale (HADS),18 Emotional Loneliness Scale,19
Caregiver Distress Scale of the Neuropsychiatric Inventory
(NPI-D),20 positive scale from the Positive and Negative Affect
Schedule (PANAS),21 Positive Aspects of Caring (PAC) using the
four-item positive aspects subscale from the Carers of Older
People in Europe Index (COPE index),22 three-item Personal
Growth Index (PGI)23 and Quality of Caregiver–Patient
Relationship (QCPR).24
Secondary outcomes for the person with dementia
These included the EQ-5D, HADS and QCPR, as for family
carers. Family carers rated the functional capacity of the person
with dementia in activities of daily living using the Alzheimer’s
Disease Cooperative Study—Activities of Daily Living Inventory
(ADCS-ADL).25 We also assessed their quality of life by the
DEMQOL,26 completed by self and carer.
Blinding
The nature of the interventions prevented us from blinding par-
ticipants and providers to their allocated group. However, we
blinded research interviewers by provided interventions inde-
pendently of their assessments. After interview, researchers
recorded their perceptions of participants’ allocation. This
showed no evidence of bias due to non-blinded researchers.
Data management and statistical analysis
We entered data into Infermed’s MACRO Electronic Data
Capture system for clinical trials. We audited a randomly
selected 10% sample of data for each site at each time point, to
ensure that the MACRO database was consistent with paper
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questionnaires. We corrected all errors and inconsistencies,
transferred the resulting data to the Statistical Package for the
Social Sciences (SPSS V.20) and undertook further checking,
notably for out-of-range values.
Where individual items were missing within scales or sub-
scales, we imputed them before calculating scale or subscale
scores. We prorated measures with at most 20% of items
missing; for example, if one of five items was missing, we
imputed this by the mean of the other four items. We also made
multiple imputations within time points, unless all measures
were missing at that point. Multiple imputations were calculated
using a linear regression model taking into account demographic
variables (carer gender, centre, carer age, living status for carer
outcomes; carer gender, person with dementia gender, centre,
carer age, person with dementia age, living status, baseline
MMSE and CDR for person with dementia outcomes),
treatment group and other scores provided at a given time
point. Using a multiple imputation method allowed an assess-
ment of the sensitivity of the data to the imputations used.
The trial statistician (ZH) carried out all statistical analyses,
mostly following a predefined analysis plan by ‘treatment allocated’.
We estimated the two main effects by comparing CSP (alone or in
combination with RYCT) with no CSP (TAU or RYCTalone); and
RYCT (alone or in combination with CSP) with no RYCT (TAU or
CSP alone), including interaction between CSP and RYCT in each
analysis. We used multilevel analysis of covariance with follow-up
data as dependent variable and baseline score as covariate. We
treated group allocation, gender and kinship as fixed effects, and
centre and time as random effects. When a main effect or inter-
action term was significant, we repeated the analysis by comparing
the combined intervention with TAU. Finally, to explore whether
‘treatment received’ could explain these pragmatic analyses by
Figure 1 Flow of participants through study.
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‘treatment allocated’, we undertook a form of dose–response ana-
lysis by adding the numbers of CSP contacts, RYCT sessions
attended and RYCTsessions attended by a CS to the model.
Patient involvement
Psychosocial interventions are a high priority for people with
dementia and family carers. Former family carers were involved
in the development and delivery of the CS intervention. Results
have been shared with study participants through a lay final
report and a stakeholder dissemination event.
RESULTS
Participant flow
Figure 1 shows the flow of participants through the trial. The
research team received 640 expressions of interest from carers
and screened all but one for eligibility. Of these, they excluded
347, notably 180 because carers declined, 66 because research-
ers could not contact carers and 33 because carer had too little
time. Of the 292 family carers who consented to the research, 1
withdrew before randomisation, but the rest completed the
baseline assessment and were randomised between January
2010 and March 2012. However, two provided no data at any
time point. As we collected no information about potential par-
ticipants before they consented, we cannot assess whether those
who participated differed from those who declined or those
whom we excluded from the trial.
Stress, time constraints or the poor health of carer or rela-
tive with dementia caused 36 carers to withdraw before the
first follow-up after 5 months; 2 of these reappeared for the
final follow-up after 12 months. Thus, 253 carers completed
the first follow-up. As 241 completed the final follow-up, we
retained 83% of the participants through 12 months. Loss to
follow-up was greater, but not significantly greater, in the TAU
group (23%) than in those allocated to 1 of the 3 interventions
(15%).
Baseline characteristics
Tables 1 and 2 show baseline demographic and clinical
characteristics of family carers and people with dementia,
respectively. Most family carers were white British (89%),
women (67%), spouses (64%) and had had only school educa-
tion (62%). Their mean age was 67 years, of which they had
spent an average of more than 4 years in caring, more than 2 of
these since diagnosis. Most people with dementia were white
British (88%), women (53%), residing with their carer (68%),
and had had only school education (75%). Their mean age was
80 years. Alzheimer’s disease was the most common diagnosis,
followed by vascular dementia, although a significant propor-
tion had no specific diagnosis recorded.
Though allocated groups were broadly similar, there were
non-significant differences that could have distorted findings if
we had not used analysis of covariance, notably people with
dementia in the TAU group were less impaired on the MMSE
Table 1 Baseline characteristics of family carers by allocated group
CSP CSP–RYCT TAU RYCT
(N=48) (N=97) (N=47) (N=97)
Characteristics/measure Level n (%) n (%) n (%) n (%)
Gender Female 29 (64) 66 (68) 30 (64) 72 (74)
Ethnicity White British 45 (94) 84 (87) 39 (83) 90 (93)
Marital status Married/cohabiting/civil 44 (92) 85 (88) 37 (79) 82 (85)
Relationship to relative with dementia Spouse/partner 32 (67) 60 (62) 29 (62) 62 (64)
Living with relative with dementia 39 (81) 78 (80) 40 (85) 73 (75)
Highest level of education School leaver (aged 14–16) 37 (77) 60 (61) 18 (38) 64 (66)
Further/higher education 11 (23) 37 (38) 29 (62) 33 (34)
Social network typology Family dependent 10 (21) 34 (35) 9 (19) 30 (32)
Locally integrated 13 (27) 32 (33) 16 (34) 29 (31)
Local self-contained 11 (23) 19 (20) 12 (26) 21 (22)
Wider community focused 4 (8.3) 4 (4.2) 8 (17) 8 (8.4)
Private 10 (21) 7 (7.3) 2 (4.3) 7 (7.4)
M (SD) M (SD) M (SD) M (SD)
Age (years) 69.0 (10.5) 65.8 (12.4) 66.8 (14.7) 66.3 (11.8)
Months of caring 58.8 (38.1) 51.2 (42.3) 52.0 (36.2) 50.94 (34.4)
SF12 V.1 (UK) Mental component* 39.4 (6.04) 39.7 (6.84) 42.5 (6.85) 38.3 (7.50)
Physical component* 36.9 (7.09) 37.8 (7.687) 39.2 (7.34) 35.8 (8.34)
EQ-5D Utility* 0.763 (0.191) 0.837 (0.179) 0.726 (0.261) 0.754 (0.255)
Self-rated global health* 74.4 (21.0) 74.3 (19.8) 63.6 (19.9) 68.1 (20.9)
HADS Total 12.0 (7.06) 11.7 (7.67) 11.7 (8.81) 13.2 (8.28)
PANAS Positive affectivity* 31.8 (7.69) 30.5 (6.81) 34.1 (7.96) 29.4 (7.36)
COPE index PAC* 12.7 (2.16) 12.6 (2.42) 12.7 (2.30) 12.6 (2.20)
Neuropsychiatric inventory Carer distress 13.5 (8.91) 11.0 (8.63) 11.5 (8.64) 13.4 (13.46)
PGI Personal growth* 14.5 (3.14) 13.5 (3.36) 15.0 (3.10) 14.0 (2.91)
QCPR QCPR total* 53.6 (9.22) 52.0 (9.56) 54.9 (8.43) 52.9 (9.28)
Loneliness 2.21 (2.04) 2.41 (2.49) 1.89 (2.36) 2.41 (2.40)
*Higher scores are better.
COPE, Carers of Older People in Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; PAC, Positive Aspects of Caring; PANAS, Positive and Negative
Affect Schedule; PGI, Personal Growth Index; QCPR, Quality of Caregiver–Patient Relationship; SF, short form.
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than other groups. To strengthen our analysis, we added MMSE
as a covariate for people with dementia. Though ethnicity
varied between groups, there was a greater variation between
centres, with the proportion of white British carers ranging
from 72% to 100%, reflecting the local populations from which
we recruited participants.
Effectiveness
Tables 3 and 4 show the results of analyses after 12 months by
treatment allocated for family carers and people with dementia,
respectively.
For family carers, there was no significant main effect or
interaction for the main outcome (health-related quality of life,
SF12). For CSP versus ‘no CSP’, the difference in means was
0.52 points on the SF-12 (95% CI −1.28 to 2.32), and for
RYCT versus ‘no RYCT’, the difference in means was 0.10
points on the SF-12 (95% CI −1.72 to 1.93). Neither was there
any main effect or interaction for any secondary outcome,
except for the quality of relationship, where imputed data
showed significant benefit for CSP over ‘no CSP’ in the ‘absence
of criticism and conflict’. The adjusted difference in means was
1.11 (95% CI 0.00 to 2.21, p=0.05). Comparison of the com-
bined intervention with TAU (table 5) showed that by
12 months, CSP–RYCT had also improved carers’ perceived
quality of the caring relationship. The difference in means was
3.13 (95% CI 0.42 to 5.83, p=0.03).
The results for people with dementia are more complex.
There was no significant main effect for the main outcome
(QoL-AD) at 12 months (CSP vs ‘no CSP’ difference in means
−0.08 points, 95% CI −1.70 to 1.56; RYCT vs ‘no RYCT’ dif-
ference in means 0.51 points, 95% CI −1.17 to 2.08).
However, the interaction between CSP and RYCTwas significant
(p=0.02), suggesting that the effectiveness of the combination
might be different. The comparison of the combined interven-
tion with TAU showed no significant effect on QoL-AD.
Instead, CSP–RYCT adversely affected proxy-reported
DEMQOL relative to TAU (difference in means −4.31, 95% CI
−8.19 to −0.44, p=0.03 at the first follow-up). Similarly, CSP
adversely affected proxy-reported DEMQOL (difference in
means −3.18, 95% CI −6.15 to −0.22, p=0.04).
Completers versus non-completers
We used Fisher’s exact tests and Mann-Whitney U tests to
compare baseline characteristics of those 241 pairs who com-
pleted the final follow-up with those 50 who withdrew before
then. However, we found no significant difference in any demo-
graphic characteristics [carers’ gender (p=0.74), age (p=0.12),
ethnicity (p=0.67), marital status (p=0.62), level of education
(p=0.76)]; dementia characteristics [type of dementia
(p=0.53), neuropsychiatric symptoms (NPI, p=0.24), time
since diagnosis (p=0.56)]; kin relations (spouses/partners vs
non-spouses p=0.37); cohabitation (p=0.12); or psychological
Table 2 Baseline characteristics of people with dementia by allocated group
CSP CSP–RYCT TAU RYCT
(N=48) (N=97) (N=47) (N=97)
Characteristic/measure Level n (%) n (%) n (%) n (%)
Gender Female 27 (56) 49 (51) 29 (62) 48 (49)
Ethnicity White British 46 (96) 81 (84) 37 (79) 89 (92)
Marital status Married/cohabiting/civil 34 (71) 68 (70) 29 (62) 65 (67)
Living situation Living alone 6 (13) 11 (11) 8 (17) 20 (21)
Cohabiting with partner 35 (73) 65 (67) 29 (62) 65 (67)
Living with others 7 (15) 21 (22) 7 (15) 10 (10)
Highest level of education School leaver (aged 14–16) 36 (75) 72 (74) 33 (70) 75 (77)
Further/higher education 10 (21) 22 (23) 11 (23) 18 (19)
Missing 2 (4.2) 3 (3.1) 3 (6.4) 4 (4.1)
CDR 0.5–1 26 (57) 57 (60) 32 (73) 61 (73)
2–3 20 (43) 38 (40) 12 (27) 23 (27)
Missing 2 2 3 13
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Age (years) 79.8 (8.18) 79.3 (7.54) 79.5 (7.32) 79.8 (8.36)
Months since diagnosis 29.6 (20.6) 30.9 (25.5) 29.8 (26.1) 33.2 (30.0)
MMSE Total* 16.3 (6.37) 17.5 (6.35) 19.7 (5.37) 16.3 (7.03)
QoL-AD Self-report* 37.1 (4.75) 35.6 (5.82) 37.6 (5.94) 36.7 (5.50)
Proxy* 30.9 (6.01) 30.0 (5.89) 32.2 (6.81) 30.7 (5.35)
DEMQOL Self-report* 93.4 (12.4) 90.6 (13.4) 92.4 (11.2) 92.1 (12.3)
Proxy* 89.3 (15.6) 94.4 (14.1) 93.5 (15.8) 93.8 (13.3)
EQ-5D Utility value* 0.693 (0.312) 0.677 (0.301) 0.763 (0.312) 0.666 (0.316)
Self-rated general health* 76.2 (18.1) 70.4 (19.4) 76.42 (16.0) 69.60 (21.2)
HADS Total 8.49 (6.27) 10.6 (6.32) 9.00 (6.28) 9.89 (6.27)
ADCS-ADL Total* 42.0 (16.4) 41.2 (18.1) 44.3 (19.4) 42.2 (17.6)
NPI Total 23.4 (17.7) 21.4 (16.9) 22.5 (17.2) 28.1 (22.3)
Quality of relationship QCPR total* 58.5 (6.11) 57.4 (6.56) 58.6 (5.96) 58.4 (6.41)
*Higher scores are better.
ADCS-ADL, Alzheimer’s Disease Cooperative Study—Activities of Daily Living; CDR, clinical dementia rating; DEMQOL, quality of life for people with dementia; EQ-5D, EuroQol 5
dimensions; HADS, Hospital Anxiety and Depression Scale; MMSE, mini-mental state examination; NPI, neuropsychiatric inventory; QCPR, Quality of Caregiver–Patient Relationship;
QoL-AD, Quality of Life in Alzheimer’s Disease Scale.
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Table 3 Outcomes for family carers after 12 months: means and differences adjusted for covariates and the other intervention
Measure
Data
set
Missing
(N=241) CSP
No
CSP MD 95% CI of MD
Significance
level RYCT
No
RYCT MD 95% CI of MD
Significance
level
Significance level
of interaction
SF12 MCS* Original 0 41.56 41.05 0.517 (−1.28 to 2.32) 0.57 41.36 41.25 0.105 (−1.72 to 1.93) 0.91 0.74
Imputed 0 41.56 41.05 0.517 (−1.28 to 2.32) 0.57 41.36 41.25 0.105 (−1.72 to 1.93) 0.91 0.74
SF12 PCS* Original 0 43.86 43.25 0.613 (−1.23 to 2.46) 0.52 43.34 43.77 −0.428 (−2.29 to 1.43) 0.65 0.98
Imputed 0 43.86 43.25 0.613 (−1.23 to 2.46) 0.52 43.34 43.77 −0.428 (−2.29 to 1.43) 0.65 0.98
EQ-5D utility* Original 6 0.77 0.72 0.0513 (−0.02 to 0.13) 0.13 0.73 0.76 −0.0250 (−0.10 to 0.05) 0.52 0.79
Imputed 0 0.77 0.71 0.0574 (−0.02 to 0.13) 0.14 0.72 0.75 −0.0310 (−0.11 to 0.05) 0.43 0.70
EQ-5D self-rated global health* Original 6 70.72 69.34 1.38 (−3.04 to 5.80) 0.32 70.17 69.90 0.274 (−4.16 to 4.70) 0.87 0.34
Imputed 0 69.73 69.35 0.384 (−4.20 to 4.96) 0.87 70.00 69.08 0.915 (−3.65 to 5.48) 0.69 0.27
HADS anxiety Original 3 6.83 7.22 −0.389 (−1.33 to 0.56) 0.22 7.19 6.85 0.336 (−0.61 to 1.28) 0.51 0.38
Imputed 0 6.91 7.26 −0.33 (−1.31 to 0.60) 0.47 7.23 6.93 0.298 (−0.65 to 1.25) 0.54 0.29
HADS depression Original 3 5.93 5.96 −0.0254 (−0.90 to 0.85) 0.84 5.93 5.96 −0.0250 (−0.91 to 0.86) 0.94 0.71
Imputed 0 5.99 5.97 0.0144 (−0.85 to 0.88) 0.97 5.95 6.02 −0.0700 (−0.95 to 0.81) 0.88 0.65
PANAS positive affectivity* Original 4 30.59 30.37 0.226 (−1.23 to 1.68) 0.77 31.02 29.94 1.07 (−0.40 to 2.56) 0.15 0.93
Imputed 0 30.47 30.30 0.163 (−1.29 to 1.62) 0.83 30.85 29.92 0.936 (−0.55 to 2.42) 0.22 0.93
COPE PAC* Original 24 12.14 12.26 −0.116 (−0.64 to 0.41) 0.70 12.26 12.14 0.114 (−0.41 to 0.64) 0.65 0.79
Imputed 0 12.13 12.11 0.0125 (−0.54 to 0.56) 0.96 12.16 12.08 0.0784 (−0.45 to 0.61) 0.77 0.93
Carer distress NPI-D Original 37 11.94 9.51 2.435 (0.14 to 4.73) 0.04 10.58 10.87 −0.294 (−2.58 to 1.99) 0.73 0.10
Imputed 0 12.63 10.82 1.819 (−0.46 to 4.10) 0.12 11.68 11.77 −0.0851 (−2.28 to 2.10) 0.94 0.40
Personal growth* Original 5 12.03 12.43 −0.396 (−0.98 to 0.19) 0.18 12.41 12.05 0.360 (−0.23 to 0.95) 0.26 0.23
Imputed 0 12.03 12.44 −0.412 (−1.00 to 0.18) 0.17 12.42 12.05 0.369 (−0.22 to 0.96) 0.22 0.23
QCPR warmth* Original 24 31.36 31.27 0.0936 (−1.11 to 1.30) 0.82 31.72 30.91 0.819 (−0.40 to 2.04) 0.17 0.69
Imputed 0 31.32 31.06 0.260 (−0.99 to 1.50) 0.68 31.63 30.74 0.892 (−0.33 to 2.12) 0.15 0.76
QCPR absence of criticism and conflict* Original 24 22.23 21.45 0.778 (−0.28 to 1.84) 0.15 22.19 21.49 0.704 (−0.35 to 1.76) 0.19 0.97
Imputed 0 22.08 20.97 1.107 (0.00 to 2.21) 0.05 22.02 21.04 0.981 (−0.15 to 2.11) 0.09 0.76
QCPR total* Original 24 53.60 52.70 0.903 (−1.03 to 2.83) 0.33 53.89 52.40 1.493 (−0.44 to 3.42) 0.12 0.81
Imputed 0 53.41 52.00 1.416 (−0.47 to 3.30) 0.14 53.64 51.77 1.869 (−0.02 to 3.75) 0.05 0.84
Loneliness Original 4 2.68 2.51 0.168 (−0.32 to 0.66) 0.61 2.47 2.71 −0.244 (−0.73 to 0.24) 0.31 0.52
Imputed 0 2.72 2.53 0.187 (−0.31 to 0.68) 0.46 2.49 2.76 −0.267 (−0.76 to 0.22) 0.29 0.40
Covariates: baseline score, carer gender, kinship and centre (random effect).
*Higher scores are better.
COPE, Carers of Older People in Europe; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; MCS, mental component score; NPI-D, Neuropsychiatric Inventory Distress Scale; PAC, Positive Aspects of Caring; PANAS, Positive and
Negative Affect Schedule; PCS, Physical Component Score; QCPR, Quality of Caregiver–Patient Relationship; SF, short form.
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Table 4 Outcomes for people with dementia after 12 months: means and differences adjusted for covariates and the other intervention
Measure
Data
set
Missing
(N=241) CSP
No
CSP MD 95% CI of MD
Significance
level RYCT
No
RYCT MD 95% CI of MD
Significance
level
Significance level
of interaction
QoL-AD self-reported* Original 101 37.85 37.93 −0.0820 (−1.70 to 1.56) 0.92 38.14 37.63 0.510 (−1.17 to 2.08) 0.58 0.51
Imputed 0 36.43 36.59 −0.162 (−1.87 to 1.54) 0.85 36.86 36.16 0.702 (−1.05 to 2.45) 0.43 0.80
QoL-AD proxy reported* Original 22 28.78 28.97 −0.200 (−1.44 to 1.05) 0.76 28.84 28.91 −0.0620 (−1.33 to 1.20) 0.92 0.02
Imputed 0 28.50 28.49 0.050 (−1.21 to 1.31) 0.94 28.52 28.47 0.0660 (−1.17 to 1.30) 0.92 0.04
DEMQOL self-reported* Original 103 96.65 94.11 2.54 (−0.67 to 5.74) 0.12 95.29 95.47 −0.173 (−3.35 to 3.00) 0.92 0.14
Imputed 0 93.99 90.87 3.12 (−0.27 to 6.51) 0.07 92.19 92.67 −0.488 (−4.17 to 3.20) 0.80 0.20
DEMQOL proxy reported* Original 24 92.41 95.59 −3.18 (−6.15 to −0.22) 0.04 93.99 94.00 0.00600 (−2.97 to 2.98) 0.99 0.08
Imputed 0 92.22 95.11 −2.90 (−5.88 to 0.08) 0.06 93.49 93.84 −0.348 (−3.46 to 2.76) 0.83 0.20
EQ-5D self-reported utility* Original 121 0.76 0.82 −0.07 (−0.17 to 0) 0.31 0.82 0.77 0.05 (−0.05 to 0.15) 0.24 0.22
Imputed 0 0.75 0.84 −0.09 (−0.17 to −0.01) 0.11 0.80 0.79 0.03 (−0.07 to 0.13) 0.54 0.11
ED-5D self-reported general
health*
Original 121 74.80 72.85 1.95 (−6.75 to 2.81) 0.51 72.95 74.70 1.74 (−6.91 to 2.52) 0.78 0.49
Imputed 0 74.38 72.82 1.57 (−6.98 to 2.27) 0.72 72.48 74.72 2.24 (−6.24 to 3.25) 0.61 0.32
HADS total Original 107 7.16 7.29 −0.132 (−1.87 to 1.60) 0.88 7.40 7.06 0.338 (−1.37 to 2.05) 0.70 0.21
Imputed 0 9.27 9.42 −0.144 (−1.77 to 1.49) 0.86 9.49 9.21 0.280 (−1.18 to 1.74) 0.71 0.68
ADCS-ADL* Original 68 40.70 42.79 −2.08 (−5.52 to 1.36) 0.24 40.18 43.31 −3.14 (−6.56 to 0.28) 0.07 0.02
Imputed 0 35.30 37.47 −2.18 (−6.07 to 1.71) 0.27 35.16 37.61 −2.45 (−5.95 to 1.06) 0.17 0.07
NPI Original 25 24.72 24.09 0.630 (−4.36 to 5.62) 0.81 25.43 23.38 2.05 (−2.98 to 7.07) 0.43 0.16
Imputed 0 27.16 28.37 −1.20 (−6.64 to 4.23) 0.66 27.88 27.65 0.236 (−4.83 to 5.30) 0.93 0.40
QCPR total* Original 104 60.50 59.66 0.841 (−1.22 to 2.90) 0.43 59.98 60.17 −0.196 (−2.22 to 1.83) 0.85 0.94
Imputed 0 57.22 57.13 0.0880 (−2.71 to 2.88) 0.95 56.88 57.47 −0.598 (−2.61 to 1.41) 0.56 0.86
Covariates: baseline and MMSE scores, participant gender, kinship and centre (random effect).
* Higher scores are better.
ADCS-ADL, Alzheimer’s Disease Cooperative Study—Activities of Daily Living; DEMQOL, quality of life for people with dementia; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; MMSE, mini-mental state examination; NPI,
neuropsychiatric inventory; QCPR, Quality of Caregiver–Patient Relationship; QoL-AD, Quality of Life in Alzheimer’s Disease Scale.
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variables [health-related quality of life (SF12 MCS, p=0.67;
SF12 PCS, p=0.82; EQ-5D utility, p=0.67); distress (NPI dis-
tress, p=0.24) or depression (HADS depression, p=0.65)].
Intervention uptake and receipt
We offered 145 carers access to CSP—48 in the CSP only arm
and 97 in the combined arm. Ninety (62%) took up the offer
by meeting a CS at least once. Uptake was higher for CSP only
(71%) than for the combined intervention (58%). On average
carers who accepted CSP spent 17.8 hours with their CS over
13.1 sessions (median 12.5, range 1–40). This was higher in the
CSP only arm (19.6 hours over 14.3 sessions) than in the com-
bined arm (16.7 hours over 12.4 sessions).
We offered 194 carers access to an RYCT programme—97 in
the RYCT only arm and 97 in the combined arm. In total, 112
(57%) attended at least 1 RYCT session, with little variation
between the RYCT only (59%) and the RYCT component of the
combined intervention (57%). Carers who attended at least 1
session attended a mean of 13.5 sessions of the possible
maximum of 19, again with little variation between the RYCT
only arm (13.1 sessions) and the combined arm (13.6 sessions).
Within the combined arm, 52 carers (54%) took up the Carer
Support and reminiscence components with 82% taking up at
least one of the interventions. More people took up CSP
without RYCT (n=21) than RYCTwithout CSP (n=7).
Reasons for declining the RYCT intervention included: existing
commitments (eg, carer’s work and luncheon clubs for the person
with dementia) especially if there was a perceived risk of jeopar-
dising them; high level of impairment, cognitive or physical, in
the person with dementia; and carer’s dislike of group settings.
Despite these variations in the ‘doses’ of CSP and RYCT
received, table 6 shows no association between outcomes and
numbers of intervention sessions received. The coefficients are
small and make little contribution to the model.
DISCUSSION
Through this trial, we sought to answer the question ‘do peer
support or reminiscence, together or separately, enhance quality
of life for family carers and people with dementia?’ There was
no indication from the trial to suggest that either peer support
or reminiscence resulted in any measurable benefit.
Primary analysis 12 months after randomisation showed no
benefit to family carers of peer support or reminiscence therapy
on their many outcome measures; the only exception is that
peer support, separately and combined with reminiscence
therapy, improved carers’ perceived relationship with the person
with dementia. Similarly, there was very little benefit to people
with dementia on their many outcome measures. The only
exception is that carers allocated to peer support rated quality
of life significantly lower for the people with dementia. The cor-
responding people with dementia reported higher, but not sig-
nificantly higher, quality of life. This may reflect the known
tendency of people with dementia to rate their quality of life
more highly than do their relatives;27 however, the carer versus
person with dementia rating discrepancy was not evident in any
of the other comparisons.
Our lack of findings are in keeping with many other rando-
mised controlled trials of psychological interventions for family
carers of people with dementia where no measurable effect has
been found for popular interventions.
Strengths and limitations
We drew participants from a wide range of community settings
and included those already embedded in services and new users
Ta
bl
e
5
Co
m
bi
ne
d
in
te
rv
en
tio
n
(C
SP
–
RY
CT
)v
er
su
s
TA
U:
ad
ju
st
ed
m
ea
ns
an
d
di
ffe
re
nc
es
w
he
n
m
ai
n
ef
fe
ct
or
in
te
ra
ct
io
n
w
as
sig
ni
fic
an
t
at
12
m
on
th
s
Fi
rs
t
fo
llo
w
-u
p
Se
co
nd
fo
llo
w
-u
p
M
ea
su
re
D
at
a
se
t
M
is
si
ng
Co
m
bi
ne
d
TA
U
M
D
95
%
CI
of
M
D
Si
gn
ifi
ca
nc
e
le
ve
l
M
is
si
ng
Co
m
bi
ne
d
TA
U
M
D
95
%
CI
of
M
D
Si
gn
ifi
ca
nc
e
le
ve
l
Ca
re
r
Q
CP
R
ab
se
nc
e
of
cr
iti
ci
sm
an
d
co
nf
lic
t*
O
rig
in
al
8
22
.2
8
21
.5
9
0.
69
(−
0.
72
to
2.
10
)
0.
34
14
22
.3
9
20
.7
6
1.
63
(0
.1
0
to
3.
15
)
0.
04
Im
pu
te
d
0
21
.9
7
21
.0
9
0.
88
(−
0.
85
to
2.
34
)
0.
24
0
22
.3
2
20
.2
1
2.
11
(0
.5
4
to
3.
69
)
0.
01
Ca
re
r
Q
CP
R
to
ta
l*
O
rig
in
al
8
55
.5
7
53
.4
3
2.
14
(−
0.
22
to
4.
50
)
0.
08
14
54
.3
5
51
.7
7
2.
59
(−
0.
27
to
5.
44
)
0.
08
Im
pu
te
d
0
54
.9
8
52
.5
1
2.
47
(−
0.
02
to
4.
97
)
0.
05
0
54
.2
0
51
.0
8
3.
13
(0
.4
2
to
5.
83
)
0.
03
Q
oL
-A
D
pr
ox
y*
†
O
rig
in
al
7
30
.7
3
31
.4
2
−
0.
69
(−
2.
34
to
0.
96
)
0.
41
12
29
.6
8
29
.8
8
−
0.
20
(−
2.
15
to
1.
75
)
0.
84
Im
pu
te
d
0
30
.4
9
31
.2
2
−
0.
73
(−
2.
40
to
0.
94
)
0.
39
0
29
.6
8
29
.8
8
−
0.
20
(−
2.
15
to
1.
75
)
0.
84
DE
M
Q
O
L
pr
ox
y*
†
O
rig
in
al
7
96
.3
7
10
0.
70
−
4.
31
(−
8.
19
to
−
0.
44
)
0.
03
12
95
.0
9
97
.4
0
−
2.
31
(−
6.
57
to
1.
94
)
0.
28
Im
pu
te
d
0
95
.6
7
99
.9
0
−
4.
23
(−
9.
08
to
−
0.
38
)
0.
03
0
94
.2
0
96
.6
7
−
2.
48
(−
6.
98
to
2.
02
)
0.
28
AD
CS
-A
DL
*†
O
rig
in
al
23
42
.5
3
43
.1
8
−
0.
65
(−
4.
70
to
3.
39
)
0.
75
35
39
.4
9
44
.0
7
−
4.
58
(−
9.
29
to
0.
13
)
0.
06
Im
pu
te
d
0
39
.1
6
40
.6
2
−
1.
46
(−
5.
47
to
2.
54
)
0.
48
0
34
.0
2
38
.4
0
−
4.
39
(−
10
.2
0
to
1.
43
)
0.
14
Co
va
ria
te
s:
ba
se
lin
e
sc
or
e,
pa
rti
ci
pa
nt
ge
nd
er
,k
in
sh
ip
an
d
ce
nt
re
(ra
nd
om
ef
fe
ct
).
*H
ig
he
r
sc
or
es
ar
e
be
tte
r.
†
M
M
SE
w
as
al
so
co
va
ria
te
in
m
od
el
s
fo
r
pe
op
le
w
ith
de
m
en
tia
.
AD
CS
-A
DL
,A
lz
he
im
er
’s
Di
se
as
e
Co
op
er
at
iv
e
St
ud
y—
Ac
tiv
iti
es
of
Da
ily
Li
vi
ng
;D
EM
Q
O
L,
qu
al
ity
of
lif
e
fo
r
pe
op
le
w
ith
de
m
en
tia
;M
M
SE
,m
in
i-m
en
ta
ls
ta
te
ex
am
in
at
io
n;
Q
CP
R,
Qu
al
ity
of
Ca
re
gi
ve
r–
Pa
tie
nt
Re
la
tio
ns
hi
p;
Q
oL
-A
D,
Qu
al
ity
of
Li
fe
in
Al
zh
ei
m
er
’s
Di
se
as
e
Sc
al
e.
Charlesworth G, et al. J Neurol Neurosurg Psychiatry 2016;87:1218–1228. doi:10.1136/jnnp-2016-313736 1225
Neurodegeneration
of those services. We adopted broad inclusion criteria reflecting
the wide range of UK settings. Both interventions benefitted
from well-developed manuals and training for all providers. The
follow-up interviewers were blind to participants’ allocations,
although participants inevitably knew which interventions they
had received. We met our recruitment and retention targets,
though the intervention groups retained slightly more (83%)
than the control group (77%). There were no harms associated
with the interventions. Of the 159 serious adverse events
recorded during the trial, 3 were attributable to RYCT;
however, none led to withdrawal.
Factorial trial designs are attractive in yielding ‘two trials for
the price of one’. We overcame the challenge of running over-
lapping interventions by sequential randomisation procedures.
However, we adapted the original trial protocol for each inter-
vention to create a protocol that could deliver both. For
example, the eligibility criteria for reminiscence therapy usually
exclude people with dementia with agitation or severe cognitive
or physical impairment. Nevertheless, we enrolled them as eli-
gible for home-based peer support. Where possible, we adapted
interventions accordingly, for example by hiring specialist trans-
port or allowing carers to attend reminiscence sessions without
their relatives. As we could not accommodate all such needs
within the interventions, however, recruitment fell, but not
below our targets.
Factorial designs are less easy to interpret. They generate four
groups, of which three receive interventions, but only one gets
TAU. However, the main analyses reduce these four groups to
two: to evaluate peer support, analysis compares those allocated
to support with or without reminiscence therapy with those not
so allocated, and to evaluate reminiscence therapy, analysis com-
pares those allocated to reminiscence with or without peer
support with those not so allocated. These analyses assume that
peer support and reminiscence do not interact in the sense that
one potentiates or weakens the other. However, three of many
interactions we tested were significant. Hence, we interpret the
corresponding non-significant main effects with caution. Though
we addressed this issue by comparing the combined intervention
with TAU, this comparison does not have as much power.
Differences between this and other studies
Intervention: In this trial, we refined both interventions better
to meet the needs of family carers, using past carers of people
with dementia rather than lay befrienders increased rapport
Table 6 Influence of treatment received on outcomes for participants with complete data at 12 months
Number of RYCT sessions
Number of RYCT sessions attended
by CS* Number of CSP sessions
Coefficient† 95% CI Coefficient† 95% CI Coefficient† 95% CI
Carer outcomes
SF12 MCS −0.0365 (−0.180 to 0.107) 0.152 (−0.163 to 0.466) 0.0823 (−0.0365 to 0.201)
SF12 PCS −0.115 (−0.262 to 0.0315) 0.220 (−0.0992 to 0.540) 0.0900 (−0.0311 to 0.211)
EQ-5D self-reported utility −0.00376 (−0.00838 to 0.000850) 0.00660 (−0.00325 to 0.0165) 0.000135 (−0.00363 to 0.00390)
EQ-5D self-rated general health −0.0606 (−0.418 to 0.296) 0.453 (−0.307 to 1.214) 0.0961 (−0.193 to 0.385)
HADS anxiety −0.00616 (−0.0821 to 0.0698) −0.107 (−0.270 to 0.0553) 0.00404 (−0.0581 to 0.0661)
HADS depression 0.00937 (−0.0602 to 0.0789) −0.145 (−0.294 to 0.00518) −0.0253 (−0.0827 to 0.0321)
HADS total 0.00790 (−0.125 to 0.141) −0.252 (−0.538 to 0.0341) −0.0256 (−0.135 to 0.0839)
PANAS positive affectivity 0.0200 (−0.0957 to 0.136) 0.157 (−0.0915 to 0.405) −0.150 (−0.110 to −0.0795)
COPE PAC 0.0103 (−0.0308 to 0.0514) 0.0407 (−0.0470 to 0.128) 0.0398 (0.00580 to 0.0737)
Carer distress NPI-D 0.0351 (−0.142 to 0.212) −0.0494 (−0.422 to 0.324) 0.0732 (−0.0755 to 0.222)
Personal growth −0.000814 (−0.0476 to 0.0460) −0.00282 (−0.105 to 0.100) 0.00681 (−0.0316 to 0.0452)
QCPR warmth −0.0222 (−0.116 to 0.0719) 0.0223 (−0.179 to 0.223) 0.0522 (−0.0260 to 0.131)
QCPR absences of criticism and conflict −0.0116 (−0.0946 to 0.0715) −0.0229 (−0.202 to 0.156) −0.0368 (−0.106 to 0.0324)
QCPR Total −0.0329 (−0.184 to 0.118) −0.0142 (−0.338 to 0.309) 0.0183 (−0.108 to 0.144)
Loneliness −0.00569 (−0.0450 to 0.0336) 0.0148 (−0.0692 to 0.0989) 0.00345 (−0.0286 to 0.0356)
Person with dementia outcomes
QoL-AD self-reported 0.0730 (−0.0632 to 0.209) −0.0483 (−0.381 to 0.284) −0.0295 (−0.135 to 0.0755)
QoL-AD proxy reported 0.0351 (−0.0650 to 0.135) −0.0531 (−0.273 to 0.167) −0.0933 (−0.175 to −0.0115)
DEMQOL self-reported 0.0891 (−0.186 to 0.364) 0.232 (−0.523 to 0.986) −0.0891 (−0.299 to 0.121)
DEMQOL proxy reported −0.0879 (−0.322 to 0.146) −0.00380 (−0.497 to 0.489) −0.0272 (−0.220 to 0.166)
HADS anxiety 0.0218 (−0.0649 to 0.108) −0.0528 (−0.289 to 0.184) 0.0126 (−0.0537 to 0.0790)
HADS depression −0.0331 (−0.121 to 0.0552) −0.0101 (−0.253 to 0.233) 0.0103 (−0.0576 to 0.0783)
HADS total −0.0182 (−0.166 to 0.129) −0.0591 (−0.461 to 0.343) 0.0175 (−0.0959 to 0.131)
ADCS-ADL 0.185 (−0.103 to 0.473) −0.261 (−0.894 to 0.373) −0.213 (−0.442 to 0.0162)
QCPR warmth 0.0643 (−0.0366 to 0.165) −0.118 (−0.400 to 0.163) 0.0163 (−0.0618 to 0.0944)
QCPR absence of criticism and conflict 0.158 (0.0514 to 0.265) −0.204 (−0.495 to 0.0833) 0.0147 (−0.0690 to 0.0985)
QCPR total −0.0166 (−0.154 to 0.121) 0.161 (−0.126 to 0.447) −0.101 (−0.210 to 0.00847)
*Combined intervention.
†Coefficients represent the mean change in outcome with change in number of sessions attended when all other variables in the model are constant; negative coefficients show that
outcomes deteriorate as attendance increases.
ADCS-ADL, Alzheimer’s Disease Cooperative Study—Activities of Daily Living; COPE, Carers of Older People in Europe; NPI-D, Neuropsychiatric Inventory Carer Distress Scale; CS, carer
supporter; DEMQOL, quality of life for people with dementia; EQ-5D, EuroQol 5 dimensions; HADS, Hospital Anxiety and Depression Scale; MCS, mental component score; PAC, Positive
Aspects of Caring; PANAS, Positive and Negative Affect Schedule; PCS, physical component score; QCPR, Quality of Caregiver–Patient Relationship; QoL-AD, Quality of Life in
Alzheimer’s Disease Scale; SF, short form.
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between participating carers and their supporters and reminis-
cence therapy put more emphasis on carer support and educa-
tion than in the REMCARE trial.
Design: We adopted a factorial design capable of evaluating
both interventions simultaneously, and testing whether they
potentiate each other.
Population: We recruited more non-white carers and people
with dementia than previous dementia care trials had performed
in the UK. There were significant differences between carers of
different ethnic backgrounds, with South Asians reporting most
distress and African Caribbean carers least.
Uptake: This varied between groups. Uptake of carer inter-
ventions in trials is often low, which threatens trials analysed by
treatment allocated. In contrast, the success of the START trial
was due at least in part to very good uptake by carers.1
Findings: The paucity of benefit to carers is consistent with
previous trials of befriending2 and reminiscence.4 However, we
did not see the REMCARE finding of increased anxiety in carers
receiving reminiscence therapy.4 Instead, our qualitative evi-
dence28 29 aligns with other evidence that peer support and
reminiscence therapy are valued and enjoyable activities.30
Previous carer intervention research has received criticism for
not studying impact on people with dementia.
Unanswered questions and future research
Peer support and reminiscence therapy are attractive in prin-
ciple, but neither has yet generated evidence of effectiveness. By
adopting a factorial design, we sought to test whether they
potentiate each other; however, this was also ineffective.
Interventions targeting people with dementia and their carers
have gained in popularity. The findings of this research raise
questions about how best to balance the needs of the family
carer and his or her relative with dementia. It also reinforces the
need to study the impact of interventions on both parties.
CONCLUSIONS
Despite enhancing the carer support component of peer
support and reminiscence, this trial confirms previous findings
that neither intervention is effective. The quantitative results are
at odds with findings from qualitative studies of the same inter-
ventions. Research in this field should now seek to identify
which carers and people with dementia can benefit from which
psychosocial interventions.
Acknowledgements The CSP–RYCT trial (ISRCTN37956201) was part of the
‘Support at Home—Interventions to Enhance Life in Dementia (SHIELD)’ research
programme. The grant holders were Professors Orrell (UCL—Chief Investigator),
Challis (Manchester), Knapp (LSE and KCL), Moniz-Cook (Hull), Russell (Swansea),
Woods (Bangor) and Dr Charlesworth (UCL). The authors thank all of the family
carers, people with dementia, and CS and RYCT volunteers; members of the
programme steering committee James Lindesay (Chair), Vincent Kirchner, Jan
Oyebode, Rachel Thompson, Elayne Dunn, Graham Stokes, David Prothero (family
carer) and data monitoring committee Jill Manthorpe (Chair) and Jennifer Hellier.
CSP–RYCT site principal investigators were Georgina Charlesworth (North East
London NHS Foundation Trust), Gwen Bonner (Berkshire Healthcare NHS Foundation
Trust), Margaret Fox and Fiona Poland (University of East Anglia for the Norfolk &
Waveney Mental Health NHS Foundation Trust site) and Sue Rey (Northamptonshire
Healthcare NHS Foundation Trust). The voluntary organisations who supported carers
included Age Concern Havering (now Tapestry), Age UK Norfolk, Carers of Barking
and Dagenham, Redbridge Respite Care Association and Waltham Forest Carers
Association. The Web-based randomisation system and MACRO databases were
developed in collaboration with North Wales Organisation for Randomised Trials in
Health (NWORTH).
Collaborators Fiona Poland is the PPI lead for this study.
Contributors GC, BW, IR and MO participated in the design and conduct of all
stages of the research. JH was programme coordinator, ZH was trial statistician, MK
was health economics adviser and IR was methodological adviser. JW, NC and KB
were trial managers at different states of the research. RYCT Consultant and trainer
was Pam Schweitzer. JW oversaw provision of the RYCT intervention throughout the
study, with groups led locally by Yvette Kusel, Janet Jones, Caroline O’Haire, Jackie
Illes, Barbara Parkinson, Dianne Collins, Gurjinder Loyal and Rebecca Whitaker.
Shaheen Ahmed gathered data on CSP intervention provision from local CS
Coordinators Anne Loxham, Mary Woodford, Maggie Playle, Liz Sturgess, Doreen
Harrison and Lumbini Vithana. Researchers Nadia Crellin, Elizabeth Harte, Alexandra
Feast, Nina Melunsky, Emma Patten, Teresa Sullivan, James Sinclair and Deepak
Sankhla collected and entered data from participating carers and people with
dementia. GC, KB, NC, ZH, JH, MK, IR, JW, BW and MO participated in all stages of
manuscript preparation and approved the final version. GC is the guarantor.
Funding The SHIELD research programme was sponsored by the North East London
NHS Foundation Trust and funded by the National Institute for Health Research
(NIHR) programme grant number RP-PG-0606-1083. Additional sources of funding
for each site: North East London; Central and East London CLRN (CEL1042):
Northampton; Leicestershire, Northamptonshire, and Rutland CLRN and Thames
Valley DeNDRoN: Norwich; Norfolk & Suffolk Health Innovation and Education
Cluster (HIEC) and East Anglia DeNDRoN: Berkshire; and Thames Valley CLRN and
Thames Valley DeNDRoN. The views expressed are those of the authors and do not
necessarily reflect those of the NHS, NIHR or the Department of Health.
Competing interests None declared.
Patient consent Consent was obtained from patients.
Ethics approval Outer North East London Research Ethics Committee approved
this study.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
terms of the Creative Commons Attribution (CC BY 4.0) license, which permits
others to distribute, remix, adapt and build upon this work, for commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/
by/4.0/
REFERENCES
1 Livingston G, Barber J, Rapaport P, et al. Clinical effectiveness of a manual-based
coping strategy programme (START, STrAtegies for RelaTives) in promoting the
mental health of carers of family members with dementia: pragmatic randomised
controlled trial. BMJ 2013;347:f6276.
2 Charlesworth GM, Shepstone L, Wilson E, et al. Befriending carers of people with
dementia: randomised controlled trial. BMJ 2008;336:1295.
3 Spector A, Thorgrimsen L, Woods B, et al. Efficacy of an evidence-based cognitive
stimulation therapy programme for people with dementia: randomised controlled
trial. Brit J Psych 2003;183:248–54.
4 Woods RT, Orrell M, Bruce E, et al. REMCARE: pragmatic multi-centre
randomised trial of reminiscence groups for people with dementia and their
family carers: effectiveness and economic analysis. PLoS One 2016;11:
e0152843.
5 National Collaborating Centre for Mental Health. Dementia: supporting people with
Dementia and their carers in health and social care (NICE Clinical Guideline 42).
National Institute for Health and Clinical Excellence, 2006.
6 Charlesworth G, Burnell K, Beecham J, et al. Peer support and reminiscence for
family carers of people with dementia: randomised controlled cost-effectiveness trial
using a factorial design. Trials 2011;12:205.
7 Craig N, Dieppe P, Macintyre S, et al. Developing and evaluating complex
interventions: the new Medical Research Council guidance. BMJ 2008;337:
a1655.
8 Charlesworth G, Burnell K, Hoe J, et al. Acceptance checklist for clinical
effectiveness pilot trials: a systematic approach. BMC Med Res Methodol
2013;13:78.
9 Schweitzer P, Bruce E. Remembering yesterday, caring today—reminiscence
in dementia care: a guide to good practice. London: Jessica Kingsley, 2008.
10 Lichstein KL, Riedel BW, Grieve R. Fair tests of clinical trials: a treatment
implementation model. Adv Behav Res Ther 1994;16:1–29.
11 Wenger GC. Support networks of older people: a guide for practitioners.
Bangor: Centre for Social Policy Research and Development, University of Wales,
1994.
12 Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for
grading the cognitive state of patients for the clinician. J Psychiatr Res
1995;12:189–98.
13 Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of
dementia. Brit J Psychiat 1985;140:566–72.
14 Jenkinson C, Layte R. Development and testing of the UK SF-12. J Health Serv Res
Policy 1997;2:14–18.
15 Ware JE, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction
of scales and preliminary tests of reliability and validity. Med Care
1996;34:220–33.
Charlesworth G, et al. J Neurol Neurosurg Psychiatry 2016;87:1218–1228. doi:10.1136/jnnp-2016-313736 1227
Neurodegeneration
16 Logsdon RG, Gibbons LE, McCurry SM, et al. Assessing quality of life in older
adults with cognitive impairment. Psychosom Med 2002;64:510–19.
17 EuroQoL Group. EuroQoL—a new facility for the measurement of health-related
quality of life. Health Policy 1994;16:199–208.
18 Snaith RP. The Hospital Anxiety and Depression Scale. Health Qual Life Outcomes
2003;1:29.
19 Stroebe W, Stroebe M, Abakoumkin G, et al. The role of loneliness and social
support in adjustment to loss: a test of attachment versus stress theory. J Pers Soc
Psychol 1996;70:1241–9.
20 Cummings L, Mega M, Gray K, et al. The neuropsychiatric inventory:
comprehensive assessment of psychopathology in dementia. Neurology
1994;44:2308–14.
21 Watson D, Clark LA, Tellegen A. Development and validation of brief measures of
positive and negative affect: the PANAS scales. J Pers Soc Psychol
1988;54:1063–70.
22 McKee KJ, Philip I, Lamura G, et al. The COPE index: a first stage
assessment of negative impact, positive value and quality of support
of caregiving in informal carers of older people. Aging Ment Health
2003;7:39–52.
23 Ryff CD, Keyes CLM. The structure of psychological well-being revisited. J Pers Soc
Psychol 1995;69:719–27.
24 Spruyette N, van Audenhove C, Lammertyn F, et al. The quality of the caregiving
relationship in informal care for older adults with dementia and chronic psychiatric
patients. Psychol Psychother 2002;75:295–311.
25 Galasko D, Bennet D, Sano M, et al. An inventory to assess activities of daily living
for clinical trials in Alzheimer’s disease. The Alzheimer Disease Cooperative Study.
Alz Dis Assoc Dis 1997;11:S33–9.
26 Smith SC, Lamping DL, Banerjee S, et al. Measurement of health-related quality of
life for people with dementia: development of a new instrument (DEMQOL) and
evaluation of current methodology. Health Technol Assess 2005;9:1–93, iii–iv.
27 Thorgrimsen L, Selwood A, Spector A, et al. Whose quality of life is it anyway?: The
validity and reliability of the Quality of Life-Alzheimer’s Disease (QoL-AD) scale.
Alzheimer Dis Assoc Disord 2003;17:201–8.
28 Brooks A, Farquharson L, Burnell K, et al. A narrative enquiry of experienced family
carers of people with dementia volunteering in a Carer Supporter Programme.
J Community Appl Soc Psychol 2014;24:491–502.
29 Melunsky N, Crellin N, Dudzinski E, et al. The experience of family carers attending
a joint reminiscence group with people with dementia: a thematic analysis.
Dementia (London) 2015;14:842–59.
30 Smith R, Greenwood N. The impact of volunteer mentoring schemes on carers of
people with dementia and volunteer mentors: a systematic review. Am J Alz Dis
Other Dement 2014;29:8–17.
1228 Charlesworth G, et al. J Neurol Neurosurg Psychiatry 2016;87:1218–1228. doi:10.1136/jnnp-2016-313736
Neurodegeneration
a factorial pragmatic randomised trial
people with dementia and their family carers: 
Peer support and reminiscence therapy for
Martin Orrell
Hoe, Martin Knapp, Ian Russell, Jennifer Wenborn, Bob Woods and 
Georgina Charlesworth, Karen Burnell, Nadia Crellin, Zoe Hoare, Juanita
doi: 10.1136/jnnp-2016-313736
online August 12, 2016
2016 87: 1218-1228 originally publishedJ Neurol Neurosurg Psychiatry 
 http://jnnp.bmj.com/content/87/11/1218
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://jnnp.bmj.com/content/87/11/1218
This article cites 27 articles, 6 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by/4.0/
use, provided the original work is properly cited. See: 
others to distribute, remix, adapt and build upon this work, for commercial
the Creative Commons Attribution (CC BY 4.0) license, which permits 
This is an Open Access article distributed in accordance with the terms of
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1390)Memory disorders (psychiatry)
 (1020)Dementia
 (226)Open access
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
